CURIUM PHARMA UK LTD.

CURIUM PHARMA UK LTD.

Company Registration Number:
09347432 (England and Wales)

Unaudited statutory accounts for the year ended 31 December 2020

Period of accounts

Start date: 1 January 2020

End date: 31 December 2020

CURIUM PHARMA UK LTD.

Contents of the Financial Statements

for the Period Ended 31 December 2020

Directors report
Profit and loss
Balance sheet
Additional notes
Balance sheet notes

CURIUM PHARMA UK LTD.

Directors' report period ended 31 December 2020

The directors present their report with the financial statements of the company for the period ended 31 December 2020

Principal activities of the company

Principal activityThe company is a wholesale distributor of radio pharmaceutical products



Directors

The directors shown below have held office during the whole of the period from
1 January 2020 to 31 December 2020

Xavier Anne Jean-Louis Defourt
Renaud Albert Gaston Dehareng
Francois Paul Pierre Labarre


The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006

This report was approved by the board of directors on
29 September 2021

And signed on behalf of the board by:
Name: Xavier Anne Jean-Louis Defourt
Status: Director

CURIUM PHARMA UK LTD.

Profit And Loss Account

for the Period Ended 31 December 2020

2020 2019


£

£
Turnover: 14,679,083 15,088,382
Cost of sales: ( 8,622,792 ) ( 8,579,713 )
Gross profit(or loss): 6,056,291 6,508,669
Distribution costs: 0 0
Administrative expenses: ( 5,519,150 ) ( 5,099,174 )
Other operating income: 0 0
Operating profit(or loss): 537,141 1,409,495
Interest receivable and similar income: 2,505 6,983
Interest payable and similar charges: ( 9,090 ) ( 2,852 )
Profit(or loss) before tax: 530,556 1,413,626
Tax: ( 162,878 ) ( 247,721 )
Profit(or loss) for the financial year: 367,678 1,165,905

CURIUM PHARMA UK LTD.

Balance sheet

As at 31 December 2020

Notes 2020 2019


£

£
Fixed assets
Tangible assets: 3 2,202,657 452,942
Total fixed assets: 2,202,657 452,942
Current assets
Stocks: 4 37,490 53,877
Debtors: 5 6,600,420 6,638,170
Cash at bank and in hand: 269,802 119,515
Total current assets: 6,907,712 6,811,562
Creditors: amounts falling due within one year: 6 ( 6,462,363 ) ( 4,968,698 )
Net current assets (liabilities): 445,349 1,842,864
Total assets less current liabilities: 2,648,006 2,295,806
Accruals and deferred income: ( 22,710 ) ( 38,188 )
Total net assets (liabilities): 2,625,296 2,257,618
Capital and reserves
Called up share capital: 1 1
Profit and loss account: 2,625,295 2,257,617
Total Shareholders' funds: 2,625,296 2,257,618

The notes form part of these financial statements

CURIUM PHARMA UK LTD.

Balance sheet statements

For the year ending 31 December 2020 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 29 September 2021
and signed on behalf of the board by:

Name: Xavier Anne Jean-Louis Defourt
Status: Director

The notes form part of these financial statements

CURIUM PHARMA UK LTD.

Notes to the Financial Statements

for the Period Ended 31 December 2020

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

    Turnover policy

    The company has suitable financial resources with a net asset position of £2,729,464. Credit risk is spread over numerous customers and the main customer is a public sector body. Order book levels remain constant and cash flow forecasting is undertaken weekly to ensure the business has enough cash resources to sustain it during the next year.Considering the above, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus, they continue to adopt the going concern basis in preparing the annual report and financial statements

    Tangible fixed assets depreciation policy

    Tangible fixed assets are stated at cost.Cost includes the original purchase price, costs directly attributable to bringing the asset to its working condition for its intended use, dismantling and restoration costs and borrowing costs capitalized.Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives, and subject to impairment reviews, on the following bases:The estimated useful lives range as follows:Plant and machinery - 10 yearsComputer equipment - 3-5 yearsLeasehold improvements - 1-5 yearsThe assets' residual values and useful lives are reviewed, and adjusted, if appropriate, at the end of each reporting period. The effect of any change is accounted for prospectively.

    Valuation information and policy

    At each balance sheet date non-financial assets not carried at fair value are assessed to determine whether there is an indication that the asset (or asset’s cash generating unit) may be impaired. If there is such an indication the recoverable amount of the asset (or asset’s cash generating unit) is compared to the carrying amount of the asset (or asset’s cash generating unit).The recoverable amount of the asset (or asset’s cash generating unit) is the higher of the fair value less costs to sell and value in use. Value in use is defined as the present value of the future cash flows before interest and tax obtainable as a result of the asset’s (or asset’s cash generating unit) continued use. These cash flows are discounted using a pre-tax discount rate that represents the current market risk-free rate and the risks inherent in the asset.If the recoverable amount of the asset (or asset’s cash generating unit) is estimated to be lower than the carrying amount, the carrying amount is reduced to its recoverable amount. An impairment loss is recognized in the profit and loss account, unless the asset has been revalued when the amount is recognized in other comprehensive income to the extent of any previously recognized revaluation. Thereafter any excess is recognized in the profit and loss account.If an impairment loss is subsequently reversed, the carrying amount of the asset (or asset’s cash generating unit) is increased to the revised estimate of its recoverable amount, but only to the extent that the revised carrying amount does not exceed the carrying amount that would have been determined (net of depreciation or amortization) had no impairment loss been recognized in prior periods. A reversal of an impairment loss is recognized in the profit and loss account.

CURIUM PHARMA UK LTD.

Notes to the Financial Statements

for the Period Ended 31 December 2020

  • 2. Employees

    2020 2019
    Average number of employees during the period 50 34

CURIUM PHARMA UK LTD.

Notes to the Financial Statements

for the Period Ended 31 December 2020

3. Tangible assets

Land & buildings Plant & machinery Fixtures & fittings Office equipment Motor vehicles Total
Cost £ £ £ £ £ £
At 1 January 2020 261,679 690,685 79,365 1,031,729
Additions 1,876,885 27,239 22,682 1,926,806
Disposals
Revaluations
Transfers
At 31 December 2020 2,138,564 717,924 102,047 2,958,535
Depreciation
At 1 January 2020 72,793 466,739 39,255 578,787
Charge for year 37,494 119,180 20,417 177,091
On disposals
Other adjustments
At 31 December 2020 110,287 585,919 59,672 755,878
Net book value
At 31 December 2020 2,028,277 132,005 42,375 2,202,657
At 31 December 2019 188,886 223,946 40,110 452,942

CURIUM PHARMA UK LTD.

Notes to the Financial Statements

for the Period Ended 31 December 2020

4. Stocks

2020 2019
£ £
Stocks 37,490 53,877
Total 37,490 53,877

CURIUM PHARMA UK LTD.

Notes to the Financial Statements

for the Period Ended 31 December 2020

5. Debtors

2020 2019
£ £
Trade debtors 1,935,058 1,905,892
Prepayments and accrued income 426,382 127,472
Other debtors 4,238,980 4,604,806
Total 6,600,420 6,638,170

CURIUM PHARMA UK LTD.

Notes to the Financial Statements

for the Period Ended 31 December 2020

6. Creditors: amounts falling due within one year note

2020 2019
£ £
Trade creditors 874,911 390,360
Taxation and social security 998,318 613,181
Accruals and deferred income 2,265,743 706,991
Other creditors 2,323,391 3,258,166
Total 6,462,363 4,968,698